Eprotirome

DB05035InvestigationalSmall molecule

Eprotirome which is a compound with promising properties for treatment of obesity and dyslipidemia. Eprotirome increases the body’s energy consumption and reduces body weight and markedly reduces blood lipids and...

Mechanism: KB2115 works by selectively stimulating the thyroid hormone receptor which is the protein in the body that mediates the effects of thyroid hormone. KB2115 has receptor and tissue selective properties and thereby negative effects on the heart can be avoided.
Curator reviewed
Primary indication: Investigated for use/treatment in hyperlipidemia, metabolic disease, and obesity.Curator reviewed
Formula / weight: C₁₈H₁₇Br₂NO₅ · 487.144 g/mol (avg)
Code names: KB-2115

Resolves to

Compound

UNII958AQ7B6R1CAS355129-15-6ChEMBLCHEMBL2035874PubChem10299876

Structure

InChIKeyVPCSYAVXDAUHLT-UHFFFAOYSA-NSMILESCC(C)C1=C(O)C=CC(OC2=C(Br)C=C(NC(=O)CC(O)=O)C=C2Br)=C1

Targets

P10828THRBP10827THRA

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Eprotirome, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account